• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PolyPid wins FDA designation for antibiotic drug reservoir

March 8, 2017 By Sarah Faulkner

PolyPid wins FDA designation for antibiotic drug reservoirPharmaceutical company PolyPid said today that its D-Plex antibiotic drug reservoir won Qualified Infectious Disease Product status from the FDA.

Under the designation, the Israel-based company’s product will be eligible for priority review, fast-track status and an additional 5 years of market exclusivity.

The D-Plex antibiotic drug reservoir is designed to prevent post-cardiac surgery sternal infection. Following surgery, the reservoir constantly releases entrapped antibiotic over the course of several weeks.

“The receipt of QIDP designation from the FDA represents an important milestone that expedites and extends the commercial path for D-Plex in the U.S.,” CEO Amir Weisberg said in prepared remarks.  “We view this QIDP designation as validation of the significant potential of D-Plex in preventing and treating surgical site infections.  We look forward to the availability of additional data by year-end 2017 from our ongoing Phase Ib/II study in Israel of D-Plex in post-cardiac surgery sternal infection.”

Data from an ongoing Phase Ib/II study of D-Plex showed no sternal infection at a 3-month follow-up point in treated patients. PolyPid reported that the reservoir is safe, as there were no adverse events related to the product.

The company plans to seek regulatory nods in the U.S. and Europe in the coming year to conduct a Phase III trial of D-Plex. PolyPid finished a pre-IND meeting with the FDA and the federal watchdog said that D-Plex can move directly into a Phase III trial in the U.S., according to the company.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: PolyPid

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS